A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study

BACKGROUND: While the cardioprotective benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors have been established in patients with cardiovascular disease (CVD), their advantages over other anti-diabetic drugs at earlier stages remain unclear. We compared the cardioprotective effects of empa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiruma, Shigenori, Shigiyama, Fumika, Hisatake, Shinji, Mizumura, Sunao, Shiraga, Nobuyuki, Hori, Masaaki, Ikeda, Takanori, Hirose, Takahisa, Kumashiro, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852076/
https://www.ncbi.nlm.nih.gov/pubmed/33530982
http://dx.doi.org/10.1186/s12933-021-01228-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852076/
https://www.ncbi.nlm.nih.gov/pubmed/33530982
http://dx.doi.org/10.1186/s12933-021-01228-3

Ejemplares similares